Extrapolation of lung pharmacokinetics of antitubercular drugs from preclinical species to humans using PBPK modelling.

The developed PBPK approach was able to extrapolate lung PK from preclinical species to humans and to predict unbound concentrations in the various TB-infected regions, unlike empirical lung models. We found that plasma free drug PK is not always a good surrogate for TB-infected tissue unbound PK.